SCHEDULE: Wasatch Advisors Updates Esperion Therapeutics Stake

Wasatch Advisors LP has filed an Amendment No. 6 to Schedule 13G, disclosing its beneficial ownership of 3.5% of Esperion Therapeutics Inc. common stock.

Summary

• Wasatch Advisors LP reported beneficial ownership of 7,061,857 shares of Esperion Therapeutics Inc. common stock.
• This represents 3.5% of the total class of securities.
• Wasatch Advisors LP holds sole voting power over 6,219,311 shares and sole dispositive power over 7,061,857 shares.
• The filing is an Amendment No. 6 to a Schedule 13G, indicating an update to a previously reported ownership position.
• Wasatch Advisors LP is classified as an investment adviser.

Sentiment

Score: 5

Explanation: Neutral. The filing is a routine disclosure of institutional ownership. While a reduction in stake (implied by being an amendment and now below 5%) could be seen negatively, it's not explicitly stated as a 'sell-off' and could be part of portfolio rebalancing. The continued significant holding indicates ongoing interest.

Positives

• Wasatch Advisors LP, a Delaware-based investment adviser, maintains a significant stake in Esperion Therapeutics Inc., indicating continued interest in the company.

Negatives

• The reported ownership of 3.5% is below the 5% threshold, and as an Amendment No. 6, it suggests a potential reduction in stake from a previous filing, which could be interpreted negatively by some investors.

Industry Context

This filing reflects an institutional investor's position in Esperion Therapeutics, a company operating in the biotechnology and pharmaceutical sector. Changes in institutional ownership are closely watched as indicators of investor sentiment towards a company's prospects within its industry.

Stakeholder Impact

• Shareholders of Esperion Therapeutics Inc. are informed of Wasatch Advisors LP's current beneficial ownership stake, which can influence market perception and trading activity.

Key Dates

Recommendation

This Schedule 13G Amendment indicates Wasatch Advisors LP's current beneficial ownership of 3.5% in Esperion Therapeutics. As this is Amendment No. 6 and the stake is now below the 5% threshold, it suggests a reduction from a previous, larger position. While a reduction by a significant institutional investor can be a negative signal, it does not provide sufficient fundamental information about Esperion Therapeutics itself to warrant an immediate 'sell' recommendation. Investors should 'hold' and conduct further due diligence on the company's operational performance and strategic direction, considering this ownership change as a potential yellow flag.

Keywords

Esperion Therapeutics, Wasatch Advisors, Schedule 13G, Institutional Ownership, Common Stock, Investment Adviser, Shareholder Disclosure, Equity Stake, Biotechnology, Pharmaceuticals